Completely agree. My investment thesis has always relied upon HIV being the backstop that limited downside risk. A succession of HIV submissions and approvals de-risks this stock substantially. I have to believe one or more ex-US HIV distribution agreement(s) will be forthcoming, as those regulatory bodies will want to see that mechanism firmly in place.